What is the preferred reference organ, spleen or parotid gland, for interpreting Prostate-Specific Membrane Antigen (PSMA) avid lesions in a Fluorine-18 (F-18) PSMA Positron Emission Tomography (PET) scan?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 25, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Reference Organ Selection for F-18 PSMA PET Scan Interpretation

For F-18 PSMA PET scans, the parotid gland is the preferred reference organ for interpreting PSMA-avid lesions, as it demonstrates superior test-retest repeatability and lower inter-reader variability compared to the spleen.

Evidence Supporting Parotid Gland as Reference

Repeatability and Reliability Data

  • The parotid gland demonstrates high repeatability for SUVmean measurements (wCOV 9.0-14.3%) on F-18-DCFPyL PET scans, making it a reliable reference standard 1

  • Minimal inter-reader variability exists for whole parotid gland measurements (bias ±0.31 for PET/CT and ±0.24 for PET/MR), supporting its use as a consistent reference organ 2

  • The parotid gland shows consistent physiologic PSMA-ligand uptake with mean SUVmax of 12.3 ± 3.9, providing a stable background for comparison 3

Tumor-to-Background Ratio Performance

  • Tumor-to-parotid ratios demonstrate significantly higher values compared to other reference organs (p = 0.008), improving lesion detection sensitivity 4

  • The parotid gland provides better tumor-to-background discrimination than spleen (p = 0.002) or kidney (p = 0.006) for F-18-DCFPyL imaging 4

Limitations of Spleen as Reference

  • The spleen shows acceptable repeatability (wCOV 9.0-14.3% for SUVmean) but does not offer superior performance over the parotid gland 1

  • Inter-subject variability is higher for parotid gland compared to liver or blood pool, but this does not diminish its utility as a reference standard when using whole-gland measurements 2

Practical Implementation Guidelines

Measurement Technique

  • Use whole parotid gland ROI with 40% SUV threshold methodology rather than small 1-cm spherical ROIs, as the latter show greater inter-reader variability 2

  • Measure SUVmean rather than SUVmax for reference organ quantification, as SUVmean demonstrates superior repeatability for large organs including parotid glands 1

Alternative Reference Organs

  • The liver can serve as an acceptable alternative reference organ, showing minimal inter-reader variability (bias ±0.82 for PET/CT) and high repeatability 2

  • Blood pool measurements show excellent inter-reader agreement but may not provide optimal tumor-to-background ratios for all lesion types 2

Clinical Context Considerations

  • For standardized reporting frameworks (PROMISE, E-PSMA), both liver and parotid glands are utilized as reference organs for patient selection and scan interpretation 1

  • The parotid gland's consistent high PSMA-ligand uptake (SUVmax 5.2-22.9 range) makes it particularly useful for identifying true PSMA-avid lesions versus background activity 3

Important Caveats

  • Avoid using small ROIs in the parotid gland, as these introduce significant measurement variability that can compromise interpretation accuracy 2

  • Be aware that parotid gland uptake can be affected by prior radiation therapy or salivary gland pathology, which may necessitate using liver as the reference organ in these specific cases 3

  • For F-18-fluciclovine (a different amino acid tracer), the parotid gland is specifically recommended as the reference organ due to very low physiological brain uptake, though this tracer is distinct from PSMA agents 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.